The Food and Drug Administration will consider drug affordability when granting companies new vouchers that speed up approvals of some treatments, the agency’s Commissioner Marty Makary told CNBC on Friday. The FDA in June announced a national priority voucher plan that aims to cut drug review times to one-to-two months for companies it says are …
Continue reading “FDA to contemplate drug affordability when rushing up approvals: Makary”









